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M O DA L I T Y - B A S E D  ( U S ,  C T,  M R I ,  P E T - C T )  I M AG I N G
O R I G I N A L  A R T I C L E 
PURPOSE 
Prostate multiparametric magnetic resonance imaging (mpMRI) has utility in detecting post-ra-
diotherapy local recurrence. We conducted a multireader study to evaluate the diagnostic per-
formance of mpMRI for local recurrence after low dose rate (LDR) brachytherapy. 
METHODS
A total of 19 patients with biochemical recurrence after LDR brachytherapy underwent 3T en-
dorectal coil mpMRI with T2-weighted imaging, dynamic contrast-enhanced imaging (DCE) and 
diffusion-weighted imaging (DWI) with pathologic confirmation. Prospective reads by an experi-
enced prostate radiologist were compared with reads from 4 radiologists of varying experience. 
Readers identified suspicious lesions and rated each MRI detection parameter. MRI-detected le-
sions were considered true-positive with ipsilateral pathologic confirmation. Inferences for sen-
sitivity, specificity, positive predictive value (PPV), kappa, and index of specific agreement were 
made with the use of bootstrap resampling.
RESULTS
Pathologically confirmed recurrence was found in 15 of 19 patients. True positive recurrences 
identified by mpMRI were frequently located in the transition zone (46.7%) and seminal vesicles 
(30%). On patient-based analysis, average sensitivity of mpMRI was 88% (standard error [SE], 
3.5%). For highly suspicious lesions, specificity of mpMRI was 75% (SE, 16.5%). On lesion-based 
analysis, the average PPV was 62% (SE, 6.7%) for all lesions and 78.7% (SE, 10.3%) for highly sus-
picious lesions. The average PPV for lesions invading the seminal vesicles was 88.8% (n=13). The 
average PPV was 66.6% (SE, 5.8%) for lesions identified with T2-weighted imaging, 64.9% (SE, 
7.3%) for DCE, and 70% (SE, 7.3%) for DWI. 
CONCLUSION
This series provides evidence that mpMRI after LDR brachytherapy is feasible with a high pa-
tient-based cancer detection rate. Radiologists of varying experience demonstrated moderate 
agreement in detecting recurrence. 
You may cite this article as: Valle LF, Greer MD, Shih JH, et al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting 
of biochemical recurrence after low dose rate brachytherapy. Diagn Interv Radiol 2018; 24: 46–53.
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The use of brachytherapy for prostate cancer has increased over the past several decades as technical im-
provements have led to enhanced efficacy 
(1). The rate of prostate cancer control with 
permanent low dose rate (LDR) brachyther-
apy alone or in combination with external 
beam radiation therapy (EBRT) is excellent, 
and may provide superior disease con-
trol compared with EBRT in some patient 
subsets (2, 3). As many as 30%–40% of 
prostate cancer patients will undergo LDR 
brachytherapy for treatment (4, 5).
Although most patients who receive 
LDR brachytherapy for prostate cancer 
will be cured of their disease, biochemical 
recurrence occurs in 3%–13% of men un-
dergoing monotherapy (6–8). Although 
biochemical recurrence after radiotherapy 
for prostate cancer is often treated with im-
mediate or delayed androgen deprivation 
therapy (ADT), documenting local recur-
rence after LDR brachytherapy may provide 
additional therapeutic options (9, 10). For 
brachytherapy practitioners, understand-
ing the patterns of local recurrence after 
treatment may inform patient selection or 
alter implant techniques in certain cases to 
optimize dosimetry. 
The use of magnetic resonance imaging 
(MRI) has enhanced the diagnosis and stag-
ing of localized prostate cancer (11). Multi-
parametric MRI (mpMRI) typically consists 
of T2-weighted imaging, diffusion-weighted 
imaging (DWI), and dynamic contrast-en-
hanced imaging (DCE) to provide anatomical 
and functional information about the pros-
tate (11) and has been shown to improve 
prostate cancer detection and risk stratifica-
tion (12). MRI has been used for detection of 
local recurrences after EBRT (13); however, 
MRI is often avoided in the setting of pri-
or LDR brachytherapy due to concerns of 
post-treatment gland texture alterations and 
artifact from permanently implanted seeds.
We sought to determine the efficacy of 
mpMRI in identifying local recurrence of 
prostate cancer in patients with biochemi-
cal recurrence after LDR brachytherapy as a 
component of treatment. We hypothesized 
that mpMRI would be effective in identify-
ing locally recurrent cancer in this setting. 
We compared prospective mpMRI reports 
with pathologic confirmation at biopsy fol-
lowing biochemical recurrence. We further 
evaluated mpMRI performance in the same 
patients using the retrospective interpreta-
tions of 4 additional blinded radiologists of 
varying experience. We compared the pa-
tient-based sensitivity and specificity and 
lesion-based positive predictive value (PPV) 
among these 5 radiologists.
Methods
Patients
All patients were enrolled on institution-
al review board approved protocols for the 
evaluation and management of prostate 
cancer and provided informed consent. All 
patients who received LDR brachytherapy 
as a component of treatment, developed 
prostate specific antigen (PSA) recurrence, 
and subsequently underwent mpMRI and 
biopsy or surgical resection at our institution 
between January 2011 and March 2016 were 
analyzed. Patients with known metastatic 
disease were excluded. Prior treatment con-
sisted of LDR brachytherapy alone or in com-
bination with EBRT and/or ADT. Biochemical 
recurrence was defined by the Phoenix con-
sensus definition of PSA nadir plus 2 ng/mL. 
MRI protocol
Prostate mpMRI scans were acquired on 
a 3T scanner (Achieva 3T-TX, Philips Health-
care) using an endorectal coil (BPX-30, Me-
drad) filled with 45 mL fluorinert (3M) and 
anterior half of a 32-channel cardiac SENSE 
coil (InVivo). Table 1 contains MRI pulse se-
quence parameters used in this study.
Image interpretation
Patient images were examined prospec-
tively by a prostate-dedicated radiologist 
(>3000 examinations evaluated over 8 
years) as part of the clinical evaluation for 
biochemical recurrence. The intraprostatic 
level (apex, mid, and base) and zone (pe-
ripheral vs. transition) of visualized lesions, 
presence of seminal vesicle (SV) lesion, 
presence of detected abnormality on each 
sequence (T2-weighted, DWI, DCE), and 
overall likelihood of representing locally 
recurrent disease were included in clinical 
reports. 
As part of the retrospective review, pa-
tient images were evaluated by 4 board 
certified radiologists at 4 separate insti-
tutions. Two of these readers were highly 
experienced in prostate mpMRI (>2000 
cases evaluated), and two were moderate-
ly experienced (<2000 cases evaluated). 
All readers were blinded to clinical and 
pathologic outcomes at surgery or biopsy 
and were instructed to detect lesions sus-
picious for recurrent prostate cancer. The 
additional readers independently recorded 
screen-captures of each identified suspi-
cious lesion, recorded the presence or ab-
sence of an abnormality on each sequence 
for each lesion, and scored the overall like-
lihood of representing recurrent disease 
using the same criteria as the initial reader. 
Further image interpretation details are in-
cluded in the supplemental materials.
Pathologic correlation
Methods of pathologic confirmation of 
prostate cancer recurrence included tran-
srectal ultrasonography (TRUS)-guided 12-
core systematic biopsy, targeted mpMRI/
TRUS fusion biopsy, radical prostatectomy 
(RP), or a combination of the above. Target-
ed mpMRI/TRUS fusion biopsy location was 
determined by the initial prospective reader 
and was directed at all suspicious lesions in 
the prostate and SV with two cores acquired 
from each target location. Biopsy and pros-
tatectomy samples were evaluated for the 
presence of cancer and treatment effect by a 
genitourinary dedicated pathologist.
mpMRI interpretations were classified as: 
true positive in the presence of an identi-
fied mpMRI lesion with ipsilateral patho-
logic confirmation of disease within the 
prostate; false positive in the presence of 
an identified mpMRI lesion without ipsi-
lateral pathologic confirmation of disease; 
and false negative in the presence of patho-
logic identification of disease without an 
identified ipsilateral mpMRI lesion. Because 
radiologists were only instructed to identi-
fy lesions suspicious for recurrent disease, 
Main points
• Although artifact is observed, multiparametric 
MRI (mpMRI) can still be performed and may 
provide useful information following low dose 
rate (LDR) brachytherapy. 
• At the patient level, mpMRI correctly detected 
pathologically confirmed lesions with a 
sensitivity of 88% (SE, 3.5%) for all lesions 
and a specificity of 75% (SE, 16.5%) for highly 
suspicious lesions.
• At the lesion level, mpMRI demonstrated 
a high cancer-detection rate of 78.7% (SE, 
10.3%) for highly suspicious lesions.
• Radiologists of varying experience 
demonstrated 54.4% (SE, 11.9%) agreement 
when detecting recurrent cancers at the 
patient level.
• Pathologically confirmed LDR brachytherapy 
recurrences identified by mpMRI were 
frequently located in the transition zone (41%) 
and seminal vesicles (32.3%).
lesion-based true negative status was not 
assigned. 
Statistical analysis
Patient-based sensitivity and specificity 
and lesion-based positive predictive value 
(PPV) were determined for each reader. A pa-
tient-based true positive identification was 
defined as any mpMRI detected lesion in a 
patient with pathologically verified recur-
rence. In patients with multiple lesions, the 
lesion with the highest likelihood of malig-
nancy determined the overall patient likeli-
hood score. PPV was defined as the propor-
tion of true positive lesions among all lesions 
detected. The averaged sensitivity, specifici-
ty, and PPV were calculated from the average 
of reader-specific sensitivity, specificity, and 
PPVs. Sensitivity, specificity, and PPV were 
determined at low, moderate, and high over-
all suspicion levels for the single reader eval-
uation, for the duplicate four reader evalua-
tion, and for all readers combined. 
Interobserver agreement was examined 
with respect to (a) patient-based assign-
ment, (b) lesion detection and (c) positivity 
scoring for each sequence (i.e., T2-weighted 
imaging, DWI, DCE). Agreement for (a) was 
determined by the kappa statistics, where-
as agreement for (b) and (c) was deter-
mined by the index of specific agreement 
(ISA), which is defined as the conditional 
probability given that one reader, randomly 
selected, makes a specific rating which will 
be consistent with another randomly se-
lected reader. 
The bootstrap resampling procedure was 
used to calculate the standard error (SE) 
of sensitivity, specificity, kappa and ISA, 
where the bootstrap sampling unit was the 
patient. The number of bootstrap samples 
was 1000. SPSS was used to for statistical 
analyses.
Results
At the time of mpMRI, the average age 
of the cohort was 66.8 years (range, 57–85 
years). The pretreatment mean PSA was 
8.0 ng/mL (range, 3.4–31.1 ng/mL) and the 
median pretreatment Gleason score was 6 
(range, 5–8). There was a mix of low (n=12), 
intermediate (n=4), high (n=2), and un-
known (n=1) risk disease by D’Amico classi-
fication. Treatment with LDR brachytherapy 
was heterogeneous in terms of dose, radio-
nuclide, adjuvant ADT, and combination 
with EBRT (Table 2). The mean time from 
implantation to recurrence was 5.25 years 
(range, 0.98–11.2 years) with a mean PSA of 
4.37 ng/mL (range, 2.14–9.00 ng/mL) and a 
mean prostate volume of 19.0 cm3 (range, 
11.0–28.4 cm3) at the time of recurrence. 
The mean time from implantation to mp-
MRI was 7.9 years (range, 1.1–15.8 years). 
Mean PSA at the time of mpMRI was 6.2 ng/
mL (range, 0.17–22.6 ng/mL). 
A total of 62 lesions were identified by 
5 radiologists in 19 patients (mean, 3.26 
lesions per patient; range, 1–6 lesions). 
Of these, 3 lesions identified in the SV did 
not have pathologic correlation and were 
therefore excluded from further analysis. Of 
the 59 remaining mpMRI lesions, 16 (27.1%) 
were identified in the peripheral zone (PZ), 
33 (55.9%) in the transition zone (TZ), and 
10 (16.9%) in the SV. 
With regard to biopsy confirmation, 14 pa-
tients underwent systematic and MRI/TRUS 
fusion biopsy, 4 patients underwent system-
atic biopsy only, and 1 patient had a fusion 
biopsy alone (Table 2). Following biopsy, 4 
patients underwent a radical prostatectomy 
and 1 underwent SV resection. Fifteen (78.9%) 
patients had at least one pathologically con-
firmed lesion on mpMRI. Among the 15 pa-
tients with local recurrence, there were 34 le-
sions confirmed as recurrent prostate cancer 
pathologically, 30 of which were identified 
by mpMRI, with a mean of 2.26 confirmed le-
sions per patient (range, 1–6 lesions). 
Patient-based sensitivity and specificity 
of mpMRI, stratified by reader-designated 
cancer likelihood score, is shown in Table 3. 
Sensitivity and specificity were influenced 
by likelihood of malignancy groupings. 
With all lesions included, the average sensi-
tivity was 88% (SE, 3.5%), and average spec-
ificity was 25% (SE, 13.3%). With a threshold 
of only high-likelihood lesions, specificity 
increased to 75% (SE, 16.5%). 
Taking all readers in consensus, 30 of 34 
pathologically detected lesions were de-
tected by at least one reader (88.2%). Of 
the four lesions not detected, two were 
discovered at prostatectomy in the SV, and 
two were detected at random biopsy in the 
PZ. Of the two missed intraprostatic lesions, 
both were in patients with diffuse disease 
and all cores positive on systematic biopsy 
(Supplemental Fig. 1). 
On lesion-based analysis, true positive 
and false positive interpretations were nu-
merous and occurred in multiple locations 
throughout the gland (Supplemental Fig. 
2). Lesion-based PPVs of mpMRI stratified by 
reader-designated cancer likelihood score 
are presented in Table 3. With enrichment 
of high-likelihood lesions, the duplicate 
readers demonstrated no significant in-
crease in PPV (P = 0.55) compared with the 
initial radiologist that evaluated the mpMRI 
images as part of routine clinical practice. 
When the lesion identifications of all read-
ers were considered together, mpMRI yield-
ed a PPV of 62% (SE, 6.7%) for all lesions. 
The PPV improved to 78.7% (SE, 10.3%) for 
lesions designated as high-likelihood of 
malignancy by readers of multiple experi-
ence levels. When considering lesion iden-
tification based on mpMRI sequence, there 
was no evidence that DWI and T2-weight-
ed imaging performed better than DCE in 
identifying biopsy-confirmed recurrent dis-
ease, with PPVs of 70% (SE, 7.3%), 66.6% (SE, 
5.8%), and 64.9% (SE, 7.3%), respectively. 
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Table 1. Multiparametric MRI sequence parameters at 3 Tesla 
Parameter T2WI DWIa High b-value DWIb DCE 
Field of view (mm) 140×140 140×140 140×140 262×262
Acquisition matrix 304×234 112×109 76×78 188×96
Repetition time (ms) 4434 4986 6987 3.7
Echo time (ms) 120 54 52 2.3
Flip angle (°) 90 90 90 8.5
Section thickness (mm), no gaps 3 3 3 3
Image reconstruction  512×512 256×256 256×256 256×256 
matrix (pixels) 
Reconstruction voxel imaging  
resolution (mm/pixel) 0.27×0.27×3.00 0.55×0.55×2.73 0.55×0.55×2.73 1.02×1.02×3.00
Time for acquisition (min:s) 2:48 4:54 3:50 5:16
aFive evenly spaced b values (0–750 s/mm2) were used for ADC map calculation.
bb=2000 s/mm2.
MRI, magnetic resonance imaging; T2WI, T2-weighted imaging; DWI, diffusion-weighted imaging; DCE, dynamic 
contrast-enhanced imaging.
Multiparametric MRI to detect local recurrence of prostate cancer • 49
Agreement between all readers is shown 
in Supplemental Table 1. On a per patient 
basis, readers demonstrated an agreement 
of 54.4% (SE, 11.9%) for the presence or ab-
sence of disease. For scoring each parameter, 
all readers demonstrated good agreement 
ranging from 71.9% to 81.1% with agree-
ment on DCE reaching 81.1% (SE, 5.7%). 
Readers exhibited greater variation for the 
location of a detected lesion, with only mod-
erate agreement at 48.2% (SE, 5.4%). On a 
per patient basis, moderately experienced 
readers had higher agreement than highly 
experienced readers (69.8% [SE, 16.1%] vs. 
43.5% [SE, 13.1%], P =  0.121). Nevertheless, 
on the lesion basis, highly experienced read-
ers tend to agree more often than moderate-
ly experienced readers (53.6% [SE, 8.5%] vs. 
38.6% [SE, 8.5%], P = 0.234).
In terms of patterns of recurrence, of 30 
true positive mpMRI lesions, 7 (23.3%) were 
located in the PZ, 14 (46.7%) were located 
in the TZ, and 9 (30%) were located in the 
SV (Table 4). Within the SV, there was a high 
prevalence of true positive lesions relative 
to false positive lesions (77.8% and 11.1%, 
respectively, Supplemental Fig. 2), with a 
representative SV lesion shown in Fig. 1. Ac-
cordingly, the average PPV for SV invasion 
was 88.5% compared with 57.1% PPV for PZ 
Table 2. Patient characteristics, treatment, and site of recurrence 
              True 
   Pre-BT  D’Amico Total BT  Prostate Prostate EBRT  Total mpMRI positive Pathology 
Pt Age  Gleason Pre-BT risk dose  D90 V100 dose  lesions lesions mpMRI sample 
no (yrs) Race score PSA grouping (Gy) Radionuclide (Gy) (%) (Gy) ADT identified identified identifications by
1 61 White 6 6.8 Low 145 I-125 173.9 99.7 N/A No 4 3 3 SB, FB, RP
2 71 White 6 9.4 Low 145 I-125 176.6 99.9 N/A No 2 2 0 SB, FB
3 57 Black 6 6.1 Low 125 Pd-103 NR NR N/A No 4 4 0 SB, FB
4 62 White 6 4 Low 100 Pd-103 104.1 91.9 N/A No 1 1 1 SB, FB
5 63 White 5 6 Low 115 Pd-103 NR NR N/A No 2 2 0 SB
6 77 Asian 6 4.4 Low 145 I-125 171.5 97.2 N/A No 4 3 3 SB
7 64 White 7 5.2 Intermediate 125 Pd-103 126.0 23.5 N/A No 3 3 1 SB, FB
8 58 White 6 4.5 Low 125 Pd-103 NR NR N/A No 3 3 0 SB
9 85 Black 8 12.99 High 100 I-125 85.0 90.0 52.5 No 4 3 3 SB, FB
10 64 White 7 7.4 Intermediate 125 Pd-103 127.0 91.1 N/A No 4 4 1 SB, FB
11 62 White 7 4.9 Intermediate 145 I-125 160 100.0 N/A No 6 6 1 SB, FB
12 65 White 6 3.6 Low 125 Pd-103 170.2 99.9 N/A No 2 2 1 SB
13 73 White 7 31.1 Intermediate 80 Pd-103 NR NR 46.8 Yes 3 3 2 SB, FB, RP
14 67 White 5 5.3 Low 115 Pd-103 100.0 76.0 N/A No 2 2 1 SB, FB, SV
15 61 Black 6 3.4 Low 125 Pd-103 119.7 87.95 N/A No 6 6 6 SB, FB, RP
16 67 Black 8 23 High 100 Pd-103 129.3 98.7 45 Yes 4 3 3 FB, RP
17 68 White 6 4.6 Low 125 Pd-103 113.9 83.6 N/A No 4 4 1 SB, FB
18 75 White 6 5.8 Low 125 Pd-103 NR NR N/A No 5 5 2 SB, FB
19 69 White 6 3.78 Low 125 Pd-103 162.9 98.5 N/A No 3 3 1 SB, FB
Pt, patient; yrs, years; BT, brachytherapy; PSA, prostate-specific antigen; Gy, Gray; EBRT, external beam radiation therapy; ADT, androgen deprivation therapy; mpMRI, multiparamet-
ric magnetic resonance imaging; I-125, iodine-125; Pd-103, palladium-103; NR, no record (i.e., records from outside facilities not retained); N/A, not applicable; SB, standard of care 
biopsy; FB, MRI-ultrasound fusion biopsy; RP, radical prostatectomy; SV, seminal vesiculectomy.
Figure 1. a–d. Multiparametric magnetic resonance imaging (mpMRI) of seminal vesicle recurrence after 
low dose rate brachytherapy. Axial  T2-weighted MRI (a), apparent diffusion coefficient (ADC) map (b), 
b-2000 diffusion-weighted imaging (DWI) (c), dynamic contrast-enhanced imaging (DCE) (d) show a 
lesion in the right seminal vesicle (arrow) in a 67-year-old man with serum PSA=3.25 ng/mL. Findings are 
consistent with recurrent prostate cancer within the right seminal vesicle. This lesion was pathologically 
confirmed as recurrent prostate cancer.
c
a
d
b
and 52.2% PPV for TZ. Additionally, of the 
14 true positive lesions localized in the TZ, 8 
were located anterior to the urethra (Table 
4, Fig. 2). True positive lesions in the apex 
accounted for 33.3% of the lesions (repre-
sentative image in Fig. 3).
Discussion
MRI has an increasing role in the diag-
nosis and management of prostate cancer 
(14). Because of concern for MRI artifact 
caused by brachytherapy seeds, mpMRI is 
rarely used in the setting of biochemical re-
currence following this treatment. We pres-
ent evidence of the feasibility and efficacy 
of prostate mpMRI in the setting of bio-
chemical recurrence after LDR brachyther-
apy.
In this cohort, we found an average pa-
tient-based sensitivity of 88% (SE, 3.5%) for 
5 radiologists of varying experience with 
54.4% agreement between readers. This 
observation suggests mpMRI is moderate-
ly effective in detecting local recurrence in 
patients after LDR brachytherapy. Detected 
lesions were likely to represent recurrent 
cancer, especially at high suspicion levels, 
reaching a PPV of 78.7%. However, mpMRI 
was not highly specific for patients with-
out evidence of local recurrence (25% for 
all lesions, 75% for high likelihood lesions). 
This finding is limited by the fact that our 
cohort included only 4 patients without bi-
opsy confirmed recurrence. Furthermore, as 
readers were only asked to detect positive 
lesions, no lesion-based negative identifi-
cations were included in this study design. 
Our results demonstrate that mpMRI is 
somewhat less effective in the post-LDR 
brachytherapy setting compared with after 
high dose rate (HDR) brachytherapy and 
EBRT. In a series of 16 patients who under-
went HDR brachytherapy, the consensus 
sensitivity of 2 readers for detecting recur-
rence was 77%, and the PPV was 68% (15). 
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Table 3. Performance of multiparametric MRI 
     Average of  Average of initial 
  Initial reader independent readers and independent readers
Patient-based sensitivity (SE)      
  Low, intermediate, & high likelihood lesions 93.3 (6.3) 86.7 (4.3) 88 (3.5)
  Intermediate & high likelihood lesions 66.7 (12.0) 76.7 (4.9) 74.7 (5.6)
  High likelihood lesions 13.3 (8.6) 43.3 (8.7) 37.3 (7.9)
Patient-based specificity (SE)      
  Low, intermediate, & high likelihood lesions 25 (21.2) 25 (12.8) 25 (13.3)
 Intermediate & high likelihood lesions 25 (21.2) 56.2 (18.7) 50 (16.8)
 High likelihood lesions 75 (21.8) 75 (15.4) 75 (16.5)
Lesion-based positive predictive value (SE)      
  Low, intermediate, & high likelihood lesions 66.7 (8.5) 60.8 (7.6) 62.0 (6.7)
         T2WI 60.0 (9.2) 68.3 (6.7) 66.6 (5.8)
         DCE 62.5 (9.7) 65.5 (8.3) 64.9 (7.3)
         DWI 52.4 (10.0) 74.4 (8.6) 70.0 (7.3)
  Intermediate & high likelihood lesions 57.9 (10.9) 68.9 (8.0) 66.7 (6.9)
  High likelihood lesions 66.7 (29.2) 81.7 (7.3) 78.7 (10.3)
Data are presented as percentage.
SE, standard error; T2WI, T2-weighted imaging; DCE, dynamic contrast-enhanced imaging; DWI, diffusion-weighted imaging.
Table 4. Patterns of recurrence 
  True positive lesions 
  n (%)
Lesion laterality 
 Left 12 (40)
 Right 12 (40)
 Midline 6 (20)
Lesion zone  
 TZ 14 (46.7)
 PZ 7 (23.3)
Lesion level  
 Apex 10 (33.3)
 Mid 18 (60)
 Base 9 (30)
Lesion location  
 Anterior 8 (26.7)
 Posterior 13 (43.3)
Seminal vesicle invasion  
 Yes 9 (30)
TZ, transition zone; PZ, peripheral zone.
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Our consensus sensitivity was comparable 
at 88.2%. Average PPV was also comparable 
at 62%. In mpMRI after EBRT, a series of 37 
men with biochemical recurrence demon-
strated a sensitivity of 76%–80%, a PPV of 
68%–72%, and a kappa of 0.722 between 
two readers (16). Importantly, when exam-
ining only lesions at high likelihood to rep-
resent recurrence, our PPV improved sub-
stantially to 78.7%, suggesting that careful 
risk-stratification of lesions at initial inter-
pretation can help overcome the effects 
of seed distortion on the cancer detection 
rate. Our reported PPV also compares fa-
vorably to that observed in the setting of 
untreated prostate cancer (17), despite ar-
tifacts from permanently implanted seeds.
mpMRI includes a number of sequenc-
es, and it is possible that the artifact intro-
duced by brachytherapy seeds may further 
alter the performance of certain sequences 
while minimally impacting others. Radia-
tion-induced changes have been demon-
strated to cause diffuse T2-weighted signal 
hypointensity, limiting the diagnostic capa-
bility of T2-weighted imaging (18). Indeed, 
in our study T2-weighted imaging did not 
perform as well as other parameters, but 
interestingly, DWI trended towards a higher 
cancer detection rate at 70% compared with 
66.6% for T2-weighted imaging and 64.9% 
for DCE. Although the differences between 
PPVs of sequences were not significant, this 
trend suggests true positivity relied on DWI, 
which depends on minimal gland distortion 
from metallic artifact. As the anterior pros-
tate and SV are the most visible after seed 
implant, and under-sampled by systematic 
biopsies, DWI may play an important role in 
detecting recurrent cancer after mpMRI. Re-
gardless, these data support that interpre-
tation relying on multiple sequences may 
optimize interpretation. 
Prior reports have suggested that DCE 
may be superior for detecting recurrent can-
cer after radiation therapy, given that the 
enhancement of post-radiation fibrosis is 
“slow and low”, which offers a good contrast 
with the usually hypervascular recurrent 
cancer (14). Other studies have examined 
mpMRI efficacy after EBRT (19–22), and ob-
served DCE to be a valuable sequence. Our 
results suggest that DCE may be easy for 
radiologists to interpret (81.1% agreement), 
though its relative low PPV (64.9%) suggests 
that metallic seed distortion may limit its 
interpretation. It is possible that the discrep-
ancy between our findings and others re-
sulted from a more heterogeneous decrease 
Figure 3. a–d. mpMRI images of recurrence after prostate LDR brachytherapy. (a) Axial T2-weighted 
MRI, (b) DCE, (c) b-2000 DWI, and (d) ADC map show an intraprostatic lesion (arrows) within the 
apex in a 78-year-old man with serum PSA=11.97 ng/mL. The lesion was pathologically confirmed as 
recurrent prostate cancer.
a
c
b
d
Figure 2. a–d. mpMRI images of recurrence after prostate LDR brachytherapy. (a) Axial T2-weighted 
MRI, (b) ADC map, (c) b-2000 DWI, and (d) DCE show an intraprostatic lesion within the midline 
mid anterior transition zone (arrows), consistent with recurrence, in a 69-year-old man with serum 
PSA=2.56 ng/mL. The lesion was pathologically confirmed as recurrent prostate cancer.
a
c
b
d
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in prostate vascularization after brachyther-
apy compared with EBRT, making it more 
difficult to interpret post-brachytherapy 
DCE (22). 
Importantly, mpMRI was also likely to cor-
rectly identify lesions in locations that are 
not typically sampled by systematic biopsy, 
such as SV, TZ, and other locations anterior 
to the urethra. These findings highlight the 
potential utility of mpMRI as a diagnostic 
strategy to guide biopsy if local salvage 
options are considered. The increasing in-
terest in the use of focal therapies or focal 
salvage approaches (23–26) necessitates a 
clear understanding of sites of recurrence 
to maximize efficacy. Further, the patterns 
of recurrence may have implications for the 
treatment of patients with brachytherapy. 
A finding of particular interest in our 
study is the pattern of recurrence. Of the 
30 true positive lesions in our cohort, 23.3% 
were in the PZ, 46.7% in the TZ, and 30% in 
the SVs. This finding may be due to a higher 
proportion of seeds deployed in the PZ with 
resultant artifact and glandular atrophy 
that complicate interpretation. Alternative-
ly, the recurrence pattern may be related to 
the brachytherapy technique. The portion 
of the prostate anterior to the urethra may 
be relatively under-dosed with traditional 
transperineal approaches due to the need 
to avoid the course of the urethra (23). 
Loading patterns that spare the urethra 
may also unintentionally under-dose tumor 
in the TZ. The use of preimplant MRI may as-
sist in the identification of lesions that may 
not be adequately treated with an implant 
or that may require a modified loading to 
enhance treatment efficacy. 
Another concerning finding in this small 
patient subset is the frequency of SV recur-
rence. Pathologically confirmed SV invasion 
was found frequently, despite the major-
ity of patients being classified as low-risk 
at the time of treatment. As few patients 
underwent MRI before treatment, the inci-
dence of occult SV invasion pretreatment 
cannot be determined. It is possible that 
SV invasion occurred as a result of direct 
extension of an intraprostatic recurrence. 
Regardless, the frequency of SV recurrence 
in this study raises a concern that the SVs 
were undertreated. Even in the combined 
EBRT and brachytherapy setting, the doses 
delivered to the majority of the SVs is below 
50 Gy. Although this dose may be sufficient 
in the vast majority of patients based on the 
low rate of recurrence after brachytherapy, 
it is possible that pretreatment MRI may 
identify patients at highest risk of occult SV 
invasion for which alternative treatment ap-
proaches may be preferred. 
This study has some limitations. The con-
clusions are based upon a small number of 
patients and thus our results require valida-
tion in larger series. Additionally, pathologic 
confirmation of disease relied predominant-
ly on systematic and targeted biopsies, as 
not all patients underwent radical prosta-
tectomy. Biopsy results alone likely underes-
timate true positive identifications, and this 
may have contributed to the false positive 
identifications we report. Although includ-
ing multiple readers adds complexity to 
our analysis, we felt it important to include 
a broad range of readers with varying ex-
perience to decrease subjectivity and to 
increase applicability of our findings. Finally, 
our patient population was heterogeneous 
in terms of initial treatment characteristics 
and method of confirmatory biopsy. 
In conclusion, we demonstrate that mp-
MRI after LDR brachytherapy recurrence is 
feasible and effective in our small series. 
Seed distortion cannot be discounted, but 
in areas not influenced by metallic artifact, 
DWI can be a valuable sequence for iden-
tifying true positive lesions. Patterns of re-
currence suggest anterior prostate as well 
as the SV should be areas of focus for op-
timizing initial diagnosis and treatment as 
well as detecting recurrence.
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